In8bio, INC.

In8bio, INC. is a publicly traded company listed on Nasdaq under the ticker INAB [2]. The company is classified by the SEC under SIC 2836, Biological Products (No Diagnostic Substances) [3]. In8bio maintains its headquarters at the Empire State Building, 350 Fifth Avenue, Suite 5330, New York, NY, 10118 [1]. The company was previously filed with the SEC under the name Incysus Therapeutics, Inc. between May 22, 2018 and September 20, 2018 [4]. According to its most recent annual report to the SEC, In8bio reported total assets of $32.3 million [5].

Something wrong or missing? Send a correction. Fixed within 24 hours.